RCN 01303Alternative Names: RCN-01303
Latest Information Update: 20 Apr 2007
At a glance
- Originator Receptron
- Mechanism of Action Thrombopoietin inhibitors; Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chemoprotection; Thrombocytopenia
Most Recent Events
- 08 May 2001 New profile
- 08 May 2001 Phase-I clinical trials for Chemotherapy-induced thrombocytopenia (Prevention and Treatment)/Chemoprotection in USA (Unknown route)